Maya Barake1, Anne Klibanski, Nicholas A Tritos. 1. Neuroendocrine Unit (M.B., A.K., N.A.T.), Department of Medicine, Massachusetts General Hospital, and Harvard Medical School (M.B., A.K., N.A.T.), Boston, Massachusetts 2114; and Bellevue University Medical Center (M.B.), 00961 Beirut, Lebanon.
Abstract
OBJECTIVE: GH deficiency is associated with decreased bone mineral density (BMD) and increased fracture risk. Because the effects of recombinant human GH (rhGH) therapy on BMD and bone mineral content have not been systematically investigated, we conducted a meta-analysis of pertinent studies. DESIGN: A thorough search of the literature (MEDLINE, EMBASE, and the Cochrane Register) was performed. Relevant studies were divided and analyzed according to their design (randomized/controlled or prospective/retrospective) and duration of rhGH therapy (≤12 months and > 12 months). RESULTS: Administration of rhGH led to a significant increase in lumbar spine (LS) and femoral neck (FN) BMD in randomized/controlled studies of more than 1 year [weighted mean difference (95% confidence interval)] of 0.038 g/cm(2) (0.011-0.065) and 0.021 g/cm(2) (0.006-0.037) at the LS and FN, respectively, and a nonsignificant drop at the same sites in studies of shorter duration. In prospective studies, a significant increase in the LS and FN BMD was obtained. On meta-regression, a negative association was observed between the change in LS and FN BMD and subjects' age and a positive association between the BMD change and treatment duration. In a subgroup analysis, the increase in LS and FN BMD was significant in men [0.048 g/cm(2) (0.033-0.064) and 0.051 g/cm(2) (0.003-0.098), respectively] but not in women. CONCLUSION: This meta-analysis suggests a beneficial effect of rhGH replacement on BMD in adults with GH deficiency. This effect is affected by gender, age, and treatment duration. Larger studies are needed to evaluate the effect of rhGH on fracture risk.
OBJECTIVE:GH deficiency is associated with decreased bone mineral density (BMD) and increased fracture risk. Because the effects of recombinant human GH (rhGH) therapy on BMD and bone mineral content have not been systematically investigated, we conducted a meta-analysis of pertinent studies. DESIGN: A thorough search of the literature (MEDLINE, EMBASE, and the Cochrane Register) was performed. Relevant studies were divided and analyzed according to their design (randomized/controlled or prospective/retrospective) and duration of rhGH therapy (≤12 months and > 12 months). RESULTS: Administration of rhGH led to a significant increase in lumbar spine (LS) and femoral neck (FN) BMD in randomized/controlled studies of more than 1 year [weighted mean difference (95% confidence interval)] of 0.038 g/cm(2) (0.011-0.065) and 0.021 g/cm(2) (0.006-0.037) at the LS and FN, respectively, and a nonsignificant drop at the same sites in studies of shorter duration. In prospective studies, a significant increase in the LS and FN BMD was obtained. On meta-regression, a negative association was observed between the change in LS and FN BMD and subjects' age and a positive association between the BMD change and treatment duration. In a subgroup analysis, the increase in LS and FN BMD was significant in men [0.048 g/cm(2) (0.033-0.064) and 0.051 g/cm(2) (0.003-0.098), respectively] but not in women. CONCLUSION: This meta-analysis suggests a beneficial effect of rhGH replacement on BMD in adults with GH deficiency. This effect is affected by gender, age, and treatment duration. Larger studies are needed to evaluate the effect of rhGH on fracture risk.
Authors: Leroy R A Lepelaars; Francesca Renda; Luca Pani; Giuseppe Pimpinella; Hubert G M Leufkens; Gianluca Trifirò; Giovanni Tafuri; Aukje K Mantel-Teeuwisse; Francesco Trotta Journal: Br J Clin Pharmacol Date: 2018-01-18 Impact factor: 4.335
Authors: Maya Barake; Asma Arabi; Nancy Nakhoul; Ghada El-Hajj Fuleihan; Sarah El Ghandour; Anne Klibanski; Nicholas A Tritos Journal: Endocrine Date: 2017-10-13 Impact factor: 3.633
Authors: Anna Aulinas; Francisco J Guarda; Elaine W Yu; Melanie S Haines; Elisa Asanza; Lisseth Silva; Nicholas A Tritos; Joseph Verbalis; Karen K Miller; Elizabeth A Lawson Journal: Neuroendocrinology Date: 2020-02-20 Impact factor: 4.914
Authors: Traver Wright; Randall Urban; William Durham; E Lichar Dillon; Kathleen M Randolph; Christopher Danesi; Charles Gilkison; Christof Karmonik; Dennis J Zgaljardic; Brent Masel; James Bishop; Richard Pyles; Rachael Seidler; Ashton H Hierholzer; Melinda Sheffield-Moore Journal: J Neurotrauma Date: 2020-01-17 Impact factor: 5.269